<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010854</url>
  </required_header>
  <id_info>
    <org_study_id>CC# 087515</org_study_id>
    <nct_id>NCT01010854</nct_id>
    <nct_alias>NCT00437801</nct_alias>
  </id_info>
  <brief_title>Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer</brief_title>
  <acronym>VPA-FEC100</acronym>
  <official_title>A Phase II Study of Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Locally Advanced or Primary Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The drugs FEC 100 (5-fluorouracil, epirubicin, and cyclophosphamide) are one of the approved&#xD;
      options to treat Locally Advanced or Primary Metastatic Breast Cancer. In this study, the&#xD;
      investigators will add another drug called Valproic Acid (VPA) to see whether this makes the&#xD;
      treatment better. The addition of Valproic Acid to chemotherapy has been studied in about 65&#xD;
      subjects with cancer and was found to be safe and tolerable. Valproic Acid is approved by the&#xD;
      Food and Drug Administration (FDA) for the treatment of seizures, mood swings, and migraine&#xD;
      headaches. It is not currently approved for cancer, which is why the investigators are&#xD;
      conducting this study.&#xD;
&#xD;
      The results of a Phase I study of Valproic Acid and FEC100 in subjects with cancer that has&#xD;
      spread has led the investigators to believe that this combination is better than just the&#xD;
      standard treatment alone. The investigators are now testing the combination in a study with&#xD;
      subjects who have either a large tumor, many lymph nodes involved or patients whose tumor has&#xD;
      spread. In addition to the treatment, a main goal of the study is to find out which subjects&#xD;
      will benefit from this combination. In the Phase I trial the investigators noticed that while&#xD;
      this combination appears to make the chemotherapy more effective, it did not appear to cause&#xD;
      more side effects induced by the chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each year, more than 200,000 patients are diagnosed with breast cancer. While recent advances&#xD;
      in diagnosis and treatment have rendered a large proportion of these patients curable, many&#xD;
      patients still present with either locally advanced or metastatic breast cancer that is not&#xD;
      amenable to potentially curative surgery. To enhance the chance of complete surgical&#xD;
      resection of the tumor, patients with very large, locally advanced or inflammatory breast&#xD;
      cancer will be offered neo-adjuvant therapy.&#xD;
&#xD;
      The use of systemic chemotherapy after the surgical therapy for patients with operable&#xD;
      disease has been associated with a 25%-35% reduction in the risk of systemic relapse (Early&#xD;
      Breast Cancer Trialists' Collaborative Group, 1998) Administration of chemotherapy prior to&#xD;
      surgery, also referred to as neoadjuvant chemotherapy is often used in patients with&#xD;
      inoperable, non-metastatic breast cancer. However more recently, neoadjuvant therapy has&#xD;
      become more commonly used as it allows the direct assessment of response to systemic therapy&#xD;
      and the collection of biological markers of therapy that are otherwise difficult to obtain.&#xD;
      Furthermore, the relative high response rate allows the ability to surgically remove the&#xD;
      tumor and achieve adequate tumor-free margins.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Premature closure for lack of efficacy.&#xD;
  </why_stopped>
  <start_date type="Actual">December 10, 2008</start_date>
  <completion_date type="Actual">July 29, 2011</completion_date>
  <primary_completion_date type="Actual">December 12, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Response at Definitive Surgery</measure>
    <time_frame>after 4 cycles of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Based on Tumor Measurement</measure>
    <time_frame>after 4 cycles of therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>VPA FEC100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valproic Acid with FEC100</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VPA FEC100</intervention_name>
    <description>oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)</description>
    <arm_group_label>VPA FEC100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed diagnosis of breast&#xD;
             cancer&#xD;
&#xD;
          -  Patients must have &quot;locally advanced&quot; adenocarcinoma of the breast:&#xD;
&#xD;
               -  tumors &gt; 2 cm without lymph node involvement (negative sentinel lymph node&#xD;
                  mapping)&#xD;
&#xD;
               -  tumors &gt; 2 cm with lymph node involvement (either by positive sentinel lymph node&#xD;
                  mapping or FNA of palpable lymph node)&#xD;
&#xD;
               -  tumors of any size that show extension to the chest wall or skin, including&#xD;
                  edema, ulceration, or satellite skin nodules&#xD;
&#xD;
               -  inflammatory carcinoma (stage IIIB) that is amenable to surgery&#xD;
&#xD;
               -  tumors of any size associated with ipsilateral internal mammary nodes (stage&#xD;
                  IIIB)&#xD;
&#xD;
               -  tumors of any size associated with ipsilateral supraclavicular lymph nodes (IIIC)&#xD;
                  without other evidence of systemic metastases&#xD;
&#xD;
               -  patients may have bilateral breast cancer if both breasts are assessible for&#xD;
                  response&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Because no dosing or adverse event data are currently available on the use of VPA in&#xD;
             combination with FEC100 in patients &lt;18 years of age, children are excluded from this&#xD;
             study&#xD;
&#xD;
          -  ECOG performance status 0 or 1 (Karnofsky &gt;80%)&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  leukocytes &gt;3,000/mcL&#xD;
&#xD;
               -  absolute neutrophil count &gt;1,500/mcL&#xD;
&#xD;
               -  platelets &gt;100,000/mcL&#xD;
&#xD;
               -  total bilirubin within 1.5 x normal institutional limits&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) &lt;2.5 X institutional upper limit of normal&#xD;
&#xD;
               -  Creatinine within normal institutional limits&#xD;
&#xD;
          -  VPA has been associated with neural tube defects in the developing human fetus, for&#xD;
             this reason and because FEC100 used in this trial are also known to be teratogenic,&#xD;
             women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation. Participating men must use condoms while on study&#xD;
             and for at least 3 months after the trial has ended. Should a woman become pregnant or&#xD;
             suspect she is pregnant while participating in this study, she should inform her&#xD;
             treating physician immediately.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not have had any prior chemotherapy within the last 2 years&#xD;
&#xD;
          -  Patients may not have been exposed to prior anthracyclines&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  Patients with known brain metastases are excluded&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to VPA or FEC100.&#xD;
&#xD;
          -  Patients with known congestive heart disease or LVEF fractions of &lt;50 % (past or&#xD;
             current), patients with known ventricular arrhythmias&#xD;
&#xD;
          -  Patients taking VPA as an anti-seizure agent or for any other indications&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Due to the teratogenic effects of VPA and FEC100, pregnant or lactating women are&#xD;
             excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Munster, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>November 6, 2009</study_first_submitted>
  <study_first_submitted_qc>November 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2009</study_first_posted>
  <results_first_submitted>November 2, 2017</results_first_submitted>
  <results_first_submitted_qc>February 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2018</results_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>advanced</keyword>
  <keyword>local</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VPA FEC100</title>
          <description>Valproic Acid with FEC100&#xD;
oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VPA FEC100</title>
          <description>Valproic Acid with FEC100&#xD;
VPA FEC100: oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="50" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Response at Definitive Surgery</title>
        <time_frame>after 4 cycles of therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPA FEC100</title>
            <description>Valproic Acid with FEC100&#xD;
oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Response at Definitive Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response Based on Tumor Measurement</title>
        <time_frame>after 4 cycles of therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPA FEC100</title>
            <description>Valproic Acid with FEC100&#xD;
oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response Based on Tumor Measurement</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>VPA FEC100</title>
          <description>Valproic Acid with FEC100&#xD;
oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Febrile neutrophenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid function, low</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Watering Eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss/alopecia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pamela Munster, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>877-827-3222</phone>
      <email>clinicaltrials@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

